Recorded live on Tuesday, November 16, 2021 • Hosted by AST's Community of Transplant Scientists (COTS)
"Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients"
(Sci Immunol. 2021 Jun 15;6(60):eabj1031. doi: 10.1126/sciimmunol.abj1031.)
In this article:
Patients with kidney failure are at increased risk for SARS-CoV-2 infection making effective vaccinations a critical need. It is not known how well mRNA vaccines induce B and plasma cell responses in dialysis patients (DP) or kidney transplant recipients (KTR) compared to healthy controls (HC). [The authors] studied humoral and B cell responses of 35 HC, 44 DP and 40 KTR... [Data] indicated that immunosuppression resulted in impaired protective immunity after mRNA vaccination, including Ig induction with corresponding generation of plasmablasts and memory B cells. Thus, there is an urgent need to improve vaccination protocols in patients after kidney transplantation or on chronic dialysis.
- Eva Schrezenmeier, MD • Charité Universitätsmedizin Berlin, Berlin, Germany
- Amandeep Bajwa, PhD • University of Tennessee Health Science Center, Memphis, TN
- Anoma Nellore, MD • University of Alabama at Birmingham (UAB) Medicine, Birmingham, AL
AST/AJT Journal Clubs are free, but registration is required.